Research programme: tryptophan hydroxylase inhibitors - Karos Pharmaceuticals

Drug Profile

Research programme: tryptophan hydroxylase inhibitors - Karos Pharmaceuticals

Alternative Names: KAR 5417; TPH1 inhibitors

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karos Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant carcinoid syndrome

Most Recent Events

  • 13 Apr 2016 Preclinical development in malignant carcinoid syndrome in USA (unspecified route)
  • 13 Apr 2016 Karos Pharmaceuticals plans proof-of-concept studies in in two or more additional indications 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top